lead position
Patents
In the first of a two-parter, lawyers at Santarelli analyse the patentability of therapeutic inventions where publication of clinical trial protocols occurs before the application's filing date
February 2, 2026
Features list
-
The emergence of big domestic drug companies is reshaping Russia’s pharmaceutical patent landscape. Mikhail Khmara and Yana Lipatova of ARS-Patent explain how originator and generic companies can navigate the country’s changing IP rules -
The UK referendum result means that London is unlikely to play host to a UPC central division court. Cristina Biggi of Bugnion makes the case for Milan taking on the role
-
Some IP owners doubt that software can be protected in Europe. David Robinson and Mike Williams of Marks & Clerk explain why they are wrong, and what owners of computer-implemented inventions can do to maximize their chances of securing a patent
-
Technological changes to the way that plants are developed and grown pose challenges to the way that plant breeders’ rights are protected. Ylva Skoglösa and Isabel Cantallops Fiol of Valea outline the problems and offer potential solutions
-
Multinational companies and SMEs will need to think carefully about whether using the Unitary Patent and the UPC will save them money. Micaela Modiano and Alessandro Sanchini of Modiano outline the factors they need to take into account
-
The UK referendum result has created confusion over the future of the Unitary Patent and the Unified Patent Court. Marianne Schaffner of Dechert argues that EU member states must push ahead with the plan
Local Insights
Sponsored by
That.Legal
Gillian Tan of That.Legal explains how accidental font licensing gaps arise in practice, and how Singapore’s compensatory copyright framework affects enforcement outcomes
Sponsored by
Inlex
Igor Charles of Inlex explains how the EUIPO Board of Appeal recognised the Givenchy 4G logo’s reputation in France, linking luxury goods to financial services under Article 8(5) of the EU Trademark Regulation
Sponsored by
Wanhuida Intellectual Property
Yue Guan of Wanhuida Intellectual Property explains how the CNIPA’s rulings on mirogabalin besylate tablets highlight the importance of formulation patent drafting and claim amendments in China’s drug patent landscape
Sponsored by
Tilleke & Gibbins
Thanh Phuong Vu of Tilleke & Gibbins explains how Vietnam’s 2025 Intellectual Property Law amendment introduces protection for partial and intangible designs under Locarno Class 32
Sponsored by
Gün and Partners
A reversal decision by the Turkish Court of Cassation clarifies when patent enforcement may trigger unfair competition liability, report Aysel Korkmaz Yatkın, Selin Sinem Erciyas, and Beste Turan Kurtoğlu of Gün and Partners
Sponsored by
Hanol IP & Law
Min Son of Hanol IP & Law explains how the decision clarifies that multiple-word trademarks can infringe if an element serves as an essential distinctive part
Sponsored by
Saint Island International Patent & Law Offices
Taiwan has stepped up trade secret enforcement through legislative reform and court practice, says Tony Tung-Yang Chang of Saint Island International Patent & Law Offices
Sponsored by
Berken IP
Emilio Berkenwald of Berken IP examines Argentina’s continued absence from the Patent Cooperation Treaty, the practical consequences for patent filing strategies, and what possible accession could mean for local and foreign applicants
Sponsored by
Inspicos
Nikolaj Riis Christensen of Inspicos considers whether the nine-month opposition period under the European Patent Convention is still fit for purpose
Sponsored by
Inventa
Diogo Antunes of Inventa examines how personalised politics and campaign merchandising are bringing trademark law into the heart of Portugal’s presidential election